tetano
Editor, Senior Moderator
NPJ Vaccines
. 2025 Jul 13;10(1):153.
doi: 10.1038/s41541-025-01203-z. Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines
Guy de Bruyn[SUP] 1 [/SUP], Haritha Adhikarla[SUP] 2 [/SUP], Caroline K Brackett[SUP] 3 [/SUP], Yichen Jia[SUP] 2 [/SUP], Premkumar Lakshmanane[SUP] 4 [/SUP], Sarah V Mudrak[SUP] 3 [/SUP], Sheetal Sawant[SUP] 3 [/SUP], Donghui Zhang[SUP] 5 [/SUP], Roman M Chicz[SUP] 6 [/SUP], Saranya Sridhar[SUP] 7 [/SUP], Georgia D Tomaras[SUP] #[/SUP][SUP] 3 [/SUP], Kelly E Seaton[SUP] #[/SUP][SUP] 3 [/SUP]
Affiliations
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.
. 2025 Jul 13;10(1):153.
doi: 10.1038/s41541-025-01203-z. Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines
Guy de Bruyn[SUP] 1 [/SUP], Haritha Adhikarla[SUP] 2 [/SUP], Caroline K Brackett[SUP] 3 [/SUP], Yichen Jia[SUP] 2 [/SUP], Premkumar Lakshmanane[SUP] 4 [/SUP], Sarah V Mudrak[SUP] 3 [/SUP], Sheetal Sawant[SUP] 3 [/SUP], Donghui Zhang[SUP] 5 [/SUP], Roman M Chicz[SUP] 6 [/SUP], Saranya Sridhar[SUP] 7 [/SUP], Georgia D Tomaras[SUP] #[/SUP][SUP] 3 [/SUP], Kelly E Seaton[SUP] #[/SUP][SUP] 3 [/SUP]
Affiliations
- PMID: 40653502
- DOI: 10.1038/s41541-025-01203-z
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.